Delving into the Latest Updates on RhoVac ApS with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

治疗性疫苗	1
合成肽疫苗	1

关联

1

项与 RhoVac ApS 相关的药物

Onilcamotide

靶点-

作用机制

免疫刺激剂

在研机构

RhoVac ApS

原研机构

RhoVac AB

在研适应症

局限性前列腺癌 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

4

项与 RhoVac ApS 相关的临床试验

EUCTR2020-004705-31-DK / Not yet recruiting临床2期

Long-term follow-up study of immune response to vaccinations with RV001 in patients enrolled in RhoVac-001 study

开始日期2021-04-26

申办/合作机构

RhoVac ApS

EUCTR2019-000951-14-DE / Unknown status临床2期

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer - BRaVac

开始日期2019-12-19

申办/合作机构

RhoVac ApS

NCT04114825 / Active, not recruiting临床2期

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).

开始日期2019-11-19

申办/合作机构

RhoVac ApS

100 项与 RhoVac ApS 相关的临床结果

登录后查看更多信息

0 项与 RhoVac ApS 相关的专利（医药）

登录后查看更多信息

100 项与 RhoVac ApS 相关的药物交易

登录后查看更多信息

100 项与 RhoVac ApS 相关的转化医学

登录后查看更多信息